Welcome to our dedicated page for 60 degrees pharmaceuticals SEC filings (Ticker: SXTP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
60 Degrees Pharmaceuticals filings document a specialty pharmaceutical issuer with Nasdaq-listed common stock and warrants, emerging-growth-company status and a business focused on medicines for vector-borne disease. Its recent Form 8-K disclosures record material events involving the company’s at-the-market equity offering program, related legal opinions, beneficial-ownership corrections, investor-presentation materials, and clinical development and regulatory strategy updates.
The filing record also covers capital-structure and governance matters, including a one-for-four reverse stock split approved through amendments to the certificate of incorporation, annual meeting voting results and Nasdaq listing-compliance notices. These disclosures frame the company’s formal reporting around ARAKODA, tafenoquine development, equity financing mechanics, security-holder votes and exchange-related requirements.
60 Degrees Pharmaceuticals, Inc. reported that on January 8, 2026 it made a new investor presentation available in connection with a webinar hosted by RedChip Companies, Inc. The presentation, furnished as Exhibit 99.1, provides updated information on the company’s clinical development timelines and regulatory strategy.
The materials are provided under Regulation FD and are stated as being furnished rather than filed, meaning they are not automatically incorporated into other securities law reports. The company notes that the presentation contains forward-looking statements and cautions that actual results may differ due to various risks and uncertainties.
60 Degrees Pharmaceuticals reported that President and CEO Geoffrey Dow, who is also a director, bought 9,670 shares of its common stock on December 15, 2025 at $0.8024 per share. Following this purchase, he directly owns 59,618 common shares of the company.
60 Degrees Pharmaceuticals President and CEO Geoffrey Dow, who also serves as a director, reported buying additional common stock in December 2025. He acquired 9,350 shares on 12/10/2025 at $0.9504 per share and 3,613 shares on 12/11/2025 at $0.9184 per share. After these transactions, he directly owned 49,948 common shares of the company.
60 Degrees Pharmaceuticals (SXTP) reported Q3 2025 results. Cash and cash equivalents were $4,115,779 as of September 30, 2025, up from $1,659,353 at year‑end, primarily reflecting equity financings completed in January, February, and July. Product revenue was $437,602, up from $135,293 a year ago, while research revenue was $90,960. The quarter’s net loss attributed to the company was $2,316,324, and net loss attributed to common stockholders was $2,443,191, or $0.66 per share.
Operating expenses totaled $2,316,397, including research and development of $809,777 and general and administrative of $1,506,620. An inventory reserve drove a cost of revenues increase and a gross loss of $100,088; the company recorded $436,561 of write‑downs for expired inventory in the quarter. Derivative liabilities measured at fair value were $797,275 among current liabilities totaling $2,197,394.
The company disclosed substantial doubt about its ability to continue as a going concern, citing accumulated losses and cash used in operations of $5,156,566 for the nine months. Common shares outstanding were 4,104,469 at quarter‑end and 4,230,448 as of November 13, 2025. During 2025, it raised net proceeds of $804,346, $908,627, and $4,281,300 through registered offerings, and established a $1,397,532 ATM program with no sales as of quarter‑end.
60 Degrees Pharmaceuticals, Inc. filed an 8-K announcing proposals for its upcoming shareholder meeting. Shareholders will vote on electing directors, increasing the 2022 Equity Incentive Plan by 250,000 shares, and approving an amendment to the certificate of incorporation to permit a reverse stock split at a ratio between 1:3 and 1:10, to be set by the Board. The company also seeks ratification of RBSM LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025 and authorization to adjourn the meeting if additional proxy solicitation is needed. The filing lists these discrete corporate governance proposals without additional financial detail.
Geoffrey S. Dow, President and CEO and a director of 60 Degrees Pharmaceuticals, Inc. (SXTP), reported an open-market purchase of company common stock on September 12, 2025. He acquired 7,201 shares at a reported price of $1.3881 per share. Following the transaction, Mr. Dow directly beneficially owns 33,372 shares and indirectly beneficially owns 11,119 shares through the Geoffrey S. Dow Revocable Trust, of which he is trustee and retains voting and dispositive control.